• Aurora Cannabis Inc. (ACB) has closed its previously announced bought deal offering of units for gross proceeds of approximately US$172.5 million
  • Aurora is an Edmonton-based company working in the cannabis industry
  • It sold 70.4 million units at a price of US$2.45 per unit
  • The net proceeds will be used for general corporate purposes
  • Aurora is expecting no further use of the at-the-market facility anytime soon
  • Aurora Cannabis Inc. (ACB) is down 8.45 per cent trading at $1.95 per share as of 1:35 p.m. ET

Aurora Cannabis Inc. (ACB) has closed a bought deal offering of units for gross proceeds of approximately US$172.5 million.

Aurora is an Edmonton-based company working in the cannabis industry for both the medical and consumer markets.

According to the company, it sold 70.4 million units at a price of US$2.45 per unit. 9.2 million units were sold according to the exercise in full of the underwriters’ over-allotment option.

Each unit includes one common share of the company and one common share purchase warrant. A single warrant can be exercised to acquire one common share for 36 months following the closing date of the offering at an exercise price of US$3.20 per warrant share, subject to adjustment in certain events.

The net proceeds will be used for general corporate purposes. As a result of this financing, Aurora is expecting no further use of the at-the-market facility anytime soon, approximately US$186 million of which remains outstanding.

Aurora Cannabis Inc. (ACB) is down 8.45 per cent trading at $1.95 per share as of 1:35 p.m. ET.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.